GluN2B-containing NMDA receptors as possible targets for the neuroprotective and antidepressant effects of fluoxetine

Neurochemistry International

Volumn 60, Issue 2, 2012, Pages 170-176

  Kiss, Janos P ^a   Szasz, Bernadett K ^a   Fodor, László ^b   Mike, Arpad ^a   Lenkey, Nora ^a   Kurkó, Dalma ^b   Nagy, József ^b   Vizi, E Sylvester ^a  

^a INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^b GEDEON RICHTER LTD   (Hungary)

Author keywords

Depression; Desipramine; Fluoxetine; GluN2B subunit; Neuroprotection; NMDA receptor subtypes; Whole cell patch clamp

Indexed keywords

DESIPRAMINE; FLUOXETINE; IFENPRODIL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 1; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2A; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; NEUROPROTECTIVE AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIDEPRESSANT ACTIVITY; ARTICLE; DRUG INHIBITION; DRUG TARGETING; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; DEPRESSIVE DISORDER; DRUG DELIVERY SYSTEMS; FEMALE; FLUOXETINE; HEK293 CELLS; HUMANS; NEUROPROTECTIVE AGENTS; PREGNANCY; PRIMARY CELL CULTURE; RATS; RECEPTORS, N-METHYL-D-ASPARTATE;

RATTUS;

EID: 84855261952     PISSN: 01970186     EISSN: 18729754     Source Type: Journal    
DOI: 10.1016/j.neuint.2011.12.005     Document Type: Article

References (61)

1. M. Acler, E. Robol, A. Fiaschi, and P. Manganotti A double blind placebo RCT to investigate the effects of serotonergic modulation on brain excitability and motor recovery in stroke patients J. Neurol. 256 2009 1152 1158
2. I.M. Anderson Meta-analytical studies on new antidepressants Br. Med. Bull. 57 2001 161 178 (Pubitemid 32612677)
3. Y.P. Auberson, H. Allgeier, S. Bischoff, K. Lingenhoehl, R. Moretti, and M. Schmutz 5-Phosphonomethylquinoxalinediones as competitive NMDA receptor antagonists with a preference for the human 1A/2A, rather than 1A/2B receptor composition Bioorg. Med. Chem. Lett. 12 2002 1099 1102 (Pubitemid 34242811)
4. R.M. Berman, A. Cappiello, A. Anand, D.A. Oren, G.R. Heninger, D.S. Charney, and J.H. Krystal Antidepressant effects of ketamine in depressed patients Biol. Psychiatry 47 2000 351 354 (Pubitemid 30109248)
5. L. Besret, D. Debruyne, P. Rioux, T. Bonvalot, M. Moulin, E. Zarifian, and J.C. Baron A comprehensive investigation of plasma and brain regional pharmacokinetics of imipramine and its metabolites during and after chronic administration in the rat J. Pharm. Sci. 85 1996 291 295 (Pubitemid 26082473)
6. N.R. Bolo, Y. Hode, J.F. Nedelec, E. Laine, G. Wagner, and J.P. Macher Brain pharmacokinetics and tissue distribution in vivo of fluvoxamine and fluoxetine by fluorine magnetic resonance spectroscopy Neuropsychopharmacology 23 2000 428 438
7. F.P. Bymaster, W. Zhang, P.A. Carter, J. Shaw, E. Chernet, L. Phebus, D.T. Wong, and K.W. Perry Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex Psychopharmacology (Berlin) 160 2002 353 361 (Pubitemid 34253277)
8. E. Castren Is mood chemistry? Nat. Rev. Neurosci. 6 2005 241 246 (Pubitemid 40342418)
9. E. Castren, V. Voikar, and T. Rantamaki Role of neurotrophic factors in depression Curr. Opin. Pharmacol. 7 2007 18 21 (Pubitemid 46238033)
10. Y.C. Chang, S.F. Tzeng, L. Yu, A.M. Huang, H.T. Lee, C.C. Huang, and C.J. Ho Early-life fluoxetine exposure reduced functional deficits after hypoxic-ischemia brain injury in rat pups Neurobiol. Dis. 24 2006 101 113 (Pubitemid 44416211)
11. F. Chollet, J. Tardy, J.F. Albucher, C. Thalamas, E. Berard, C. Lamy, Y. Bejot, S. Deltour, A. Jaillard, P. Niclot, B. Guillon, T. Moulin, P. Marque, J. Pariente, C. Arnaud, and I. Loubinoux Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial Lancet Neurol. 10 2011 123 130
12. M. Dam, P. Tonin, A. De Boni, G. Pizzolato, S. Casson, M. Ermani, U. Freo, L. Piron, and L. Battistin Effects of fluoxetine and maprotiline on functional recovery in poststroke hemiplegic patients undergoing rehabilitation therapy Stroke 27 1996 1211 1214 (Pubitemid 26226957)
13. R.S. Duman Role of neurotrophic factors in the etiology and treatment of mood disorders Neuromol. Med. 5 2004 11 25 (Pubitemid 38391953)
14. G. Ellison The N-methyl-d-aspartate antagonists phencyclidine, ketamine and dizocilpine as both behavioral and anatomical models of the dementias Brain Res. Brain Res. Rev. 20 1995 250 267
15. K. Erreger, S.M. Dravid, T.G. Banke, D.J. Wyllie, and S.F. Traynelis Subunit-specific gating controls rat NR1/NR2A and NR1/NR2B NMDA channel kinetics and synaptic signalling profiles J. Physiol. 563 2005 345 358 (Pubitemid 40360896)
16. K.R. Gogas Glutamate-based therapeutic approaches: NR2B receptor antagonists Curr. Opin. Pharmacol. 6 2006 68 74 (Pubitemid 43103821)
17. G.E. Hardingham, Y. Fukunaga, and H. Bading Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways Nat. Neurosci. 5 2002 405 414 (Pubitemid 34454245)
18. E.C. Hennings, J.P. Kiss, K. De Oliveira, P.T. Toth, and E.S. Vizi Nicotinic acetylcholine receptor antagonistic activity of monoamine uptake blockers in rat hippocampal slices J. Neurochem. 73 1999 1043 1050 (Pubitemid 29395460)
19. E.C. Hennings, J.P. Kiss, and E.S. Vizi Nicotinic acetylcholine receptor antagonist effect of fluoxetine in rat hippocampal slices Brain Res. 759 1997 292 294 (Pubitemid 27286708)
20. S.A. Horsfield, R.B. Rosse, V. Tomasino, B.L. Schwartz, J. Mastropaolo, and S.I. Deutsch Fluoxetine's effects on cognitive performance in patients with traumatic brain injury Int. J. Psychiatry Med. 32 2002 337 344 (Pubitemid 36539084)
21. H. Kim do, H. Li, K.Y. Yoo, B.H. Lee, I.K. Hwang, and M.H. Won Effects of fluoxetine on ischemic cells and expressions in BDNF and some antioxidants in the gerbil hippocampal CA1 region induced by transient ischemia Exp. Neurol. 204 2007 748 758 (Pubitemid 46497064)
22. J.H. Krystal, G. Sanacora, H. Blumberg, A. Anand, D.S. Charney, G. Marek, C.N. Epperson, A. Goddard, and G.F. Mason Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments Mol. Psychiatry 7 Suppl. 1 2002 S71 S80
23. J.H. Krystal, D.F. Tolin, G. Sanacora, S.A. Castner, G.V. Williams, D.E. Aikins, R.E. Hoffman, and D.C. D'Souza Neuroplasticity as a target for the pharmacotherapy of anxiety disorders, mood disorders, and schizophrenia Drug Discov. Today 14 2009 690 697
24. D. Kurko, P. Dezso, A. Boros, S. Kolok, L. Fodor, J. Nagy, and Z. Szombathelyi Inducible expression and pharmacological characterization of recombinant rat NR1a/NR2A NMDA receptors Neurochem. Int. 46 2005 369 379 (Pubitemid 40292717)
25. R.T. Layer, P. Popik, T. Olds, and P. Skolnick Antidepressant-like actions of the polyamine site NMDA antagonist, eliprodil (SL-82.0715) Pharmacol. Biochem. Behav. 52 1995 621 627
26. N. Lenkey, R. Karoly, J.P. Kiss, B.K. Szasz, E.S. Vizi, and A. Mike The mechanism of activity-dependent sodium channel inhibition by the antidepressants fluoxetine and desipramine Mol. Pharmacol. 70 2006 2052 2063 (Pubitemid 44771921)
27. J.H. Li, Y.H. Wang, B.B. Wolfe, K.E. Krueger, L. Corsi, G. Stocca, and S. Vicini Developmental changes in localization of NMDA receptor subunits in primary cultures of cortical neurons Eur. J. Neurosci. 10 1998 1704 1715 (Pubitemid 28327317)
28. C.M. Lim, S.W. Kim, J.Y. Park, C. Kim, S.H. Yoon, and J.K. Lee Fluoxetine affords robust neuroprotection in the postischemic brain via its anti-inflammatory effect J. Neurosci. Res. 87 2009 1037 1045
29. Y. Liu, T.P. Wong, M. Aarts, A. Rooyakkers, L. Liu, T.W. Lai, D.C. Wu, J. Lu, M. Tymianski, A.M. Craig, and Y.T. Wang NMDA receptor subunits have differential roles in mediating excitotoxic neuronal death both in vitro and in vivo J. Neurosci. 27 2007 2846 2857 (Pubitemid 46438991)
30. I. Loubinoux, and F. Chollet Neuropharmacology in stroke recovery S.C. Cramer, R.J. Nudo, Brain Repair after Stroke 2010 Cambridge University Press Cambridge 183 193
31. H.K. Manji, J.A. Quiroz, J. Sporn, J.L. Payne, K. Denicoff, N. Gray, G. Chen, C.A. Zarate Jr.; and D.S. Charney Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression Biol. Psychiatry 53 2003 707 742 (Pubitemid 39658487)
32. J.F. Maya Vetencourt, A. Sale, A. Viegi, L. Baroncelli, R. De Pasquale, O.F. O'Leary, E. Castren, and L. Maffei The antidepressant fluoxetine restores plasticity in the adult visual cortex Science 320 2008 385 388 (Pubitemid 351555663)
33. L. Mony, J.N. Kew, M.J. Gunthorpe, and P. Paoletti Allosteric modulators of NR2B-containing NMDA receptors: molecular mechanisms and therapeutic potential Br. J. Pharmacol. 157 2009 1301 1317
34. H. Monyer, N. Burnashev, D.J. Laurie, B. Sakmann, and P.H. Seeburg Developmental and regional expression in the rat brain and functional properties of four NMDA receptors Neuron 12 1994 529 540 (Pubitemid 24100885)
35. H. Monyer, R. Sprengel, R. Schoepfer, A. Herb, M. Higuchi, H. Lomeli, N. Burnashev, B. Sakmann, and P.H. Seeburg Heteromeric NMDA receptors: molecular and functional distinction of subtypes Science 256 1992 1217 1221
36. L. Musazzi, G. Racagni, and M. Popoli Stress, glucocorticoids and glutamate release: effects of antidepressant drugs Neurochem. Int. 59 2011 138 149
37. J. Nagy, A. Boros, P. Dezso, S. Kolok, and L. Fodor Inducible expression and pharmacology of recombinant NMDA receptors, composed of rat NR1a/NR2B subunits Neurochem. Int. 43 2003 19 29 (Pubitemid 36246523)
38. A. Palucha, and A. Pilc The involvement of glutamate in the pathophysiology of depression Drug News Perspect. 18 2005 262 268 (Pubitemid 41094930)
39. E. Panconi, J. Roux, M. Altenbaumer, S. Hampe, and R.D. Porsolt MK-801 and enantiomers: potential antidepressants or false positives in classical screening models? Pharmacol. Biochem. Behav. 46 1993 15 20
40. P. Paoletti, and J. Neyton NMDA receptor subunits: function and pharmacology Curr. Opin. Pharmacol. 7 2007 39 47 (Pubitemid 46238036)
41. M. Papp, and E. Moryl Antidepressant activity of non-competitive and competitive NMDA receptor antagonists in a chronic mild stress model of depression Eur. J. Pharmacol. 263 1994 1 7 (Pubitemid 24290246)
42. J. Pariente, I. Loubinoux, C. Carel, J.F. Albucher, A. Leger, C. Manelfe, O. Rascol, and F. Chollet Fluoxetine modulates motor performance and cerebral activation of patients recovering from stroke Ann. Neurol. 50 2001 718 729 (Pubitemid 33116131)
43. I.A. Paul, and P. Skolnick Glutamate and depression: clinical and preclinical studies Ann. NY Acad. Sci. 1003 2003 250 272 (Pubitemid 38083061)
44. A.M. Redmond, J.P. Kelly, and B.E. Leonard Behavioural and neurochemical effects of dizocilpine in the olfactory bulbectomized rat model of depression Pharmacol. Biochem. Behav. 58 1997 355 359 (Pubitemid 27394285)
45. Z. Rogoz, G. Skuza, J. Maj, and W. Danysz Synergistic effect of uncompetitive NMDA receptor antagonists and antidepressant drugs in the forced swimming test in rats Neuropharmacology 42 2002 1024 1030 (Pubitemid 34790257)
46. A.L. Sheldon, and M.B. Robinson The role of glutamate transporters in neurodegenerative diseases and potential opportunities for intervention Neurochem. Int. 51 2007 333 355 (Pubitemid 47503456)
47. M. Sheng, J. Cummings, L.A. Roldan, Y.N. Jan, and L.Y. Jan Changing subunit composition of heteromeric NMDA receptors during development of rat cortex Nature 368 1994 144 147 (Pubitemid 24101524)
48. P. Skolnick, P. Popik, and R. Trullas Glutamate-based antidepressants: 20 years on Trends Pharmacol. Sci. 30 2009 563 569
49. R. Stryjer, R.D. Strous, G. Shaked, F. Bar, B. Feldman, M. Kotler, L. Polak, S. Rosenzcwaig, and A. Weizman Amantadine as augmentation therapy in the management of treatment-resistant depression Int. Clin. Psychopharmacol. 18 2003 93 96 (Pubitemid 36343978)
50. B.K. Szasz, A. Mike, R. Karoly, Z. Gerevich, P. Illes, E.S. Vizi, and J.P. Kiss Direct inhibitory effect of fluoxetine on N-methyl-d-aspartate receptors in the central nervous system Biol. Psychiatry 62 2007 1303 1309 (Pubitemid 350060896)
51. B.K. Szasz, E.S. Vizi, and J.P. Kiss Nicotinic acetylcholine receptor antagonistic property of the selective dopamine uptake inhibitor, GBR-12909 in rat hippocampal slices Neuroscience 145 2007 344 349 (Pubitemid 46227717)
52. C.G. Thomas, A.J. Miller, and G.L. Westbrook Synaptic and extrasynaptic NMDA receptor NR2 subunits in cultured hippocampal neurons J. Neurophysiol. 95 2006 1727 1734
53. R. Trullas, and P. Skolnick Functional antagonists at the NMDA receptor complex exhibit antidepressant actions Eur. J. Pharmacol. 185 1990 1 10 (Pubitemid 20254891)
54. P. Vanhoutte, and H. Bading Opposing roles of synaptic and extrasynaptic NMDA receptors in neuronal calcium signalling and BDNF gene regulation Curr. Opin. Neurobiol. 13 2003 366 371 (Pubitemid 36792249)
55. E.S. Vizi, A. Fekete, R. Karoly, and A. Mike Non-synaptic receptors and transporters involved in brain functions and targets of drug treatment Br. J. Pharmacol. 160 2010 785 809
56. E.S. Vizi, and A. Mike Nonsynaptic receptors for GABA and glutamate Curr. Top. Med. Chem. 6 2006 941 948 (Pubitemid 43796954)
57. K. Williams Ifenprodil discriminates subtypes of the N-methyl-d-aspartate receptor: selectivity and mechanisms at recombinant heteromeric receptors Mol. Pharmacol. 44 1993 851 859 (Pubitemid 23317299)
58. C.A. Zarate Jr.; J.B. Singh, P.J. Carlson, N.E. Brutsche, R. Ameli, D.A. Luckenbaugh, D.S. Charney, and H.K. Manji A randomized trial of an N-methyl-d-aspartate antagonist in treatment-resistant major depression Arch. Gen. Psychiatry 63 2006 856 864 (Pubitemid 44188478)
59. J. Zhong, S.L. Russell, D.B. Pritchett, P.B. Molinoff, and K. Williams Expression of mRNAs encoding subunits of the N-methyl-d-aspartate receptor in cultured cortical neurons Mol. Pharmacol. 45 1994 846 853 (Pubitemid 24155774)
60. M. Zhou, and M. Baudry Developmental changes in NMDA neurotoxicity reflect developmental changes in subunit composition of NMDA receptors J. Neurosci. 26 2006 2956 2963
61. S. Zittel, C. Weiller, and J. Liepert Citalopram improves dexterity in chronic stroke patients Neurorehabil Neural Repair 22 2008 311 314 (Pubitemid 351561669)